Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Annals of Surgical Oncology|May 18, 2022
Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves SurvivalAnne E O'Shea, Phillip M Kemp Bohan, Elizabeth L Carpenter, et al.
Annals of Surgical Oncology|February 10, 2021
Rates, Predictors, and Outcomes of Portal Lymphadenectomy for Resectable Gallbladder CancerPhillip M Kemp Bohan, Anne E O'Shea, Oriana V Ellis, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2020
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreementPhillip M Kemp Bohan, Robert C Chick, Annelies T Hickerson, et al.
Surgical Oncology|January 8, 2021
Lymph node sampling in resectable hepatocellular carcinoma: national practice patterns and predictors of positive lymph nodesPhillip M Kemp Bohan, Anne E O'Shea, Andrew J Lee, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 30, 2021
Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent ProgressionPhillip M Kemp Bohan, Robert C Chick, Anne E O'Shea, et al.
Clinical Immunology (Orlando, Fla.)|August 16, 2022
Immunologic and dose dependent effects of rapamycin and its evolving role in chemopreventionAnne E O'Shea, Franklin A Valdera, Daniel Ensley, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.
The Journal of Trauma and Acute Care Surgery|February 23, 2017
Damage control laparotomy utilization rates are highly variable among Level I trauma centers: Pragmatic, Randomized Optimal Platelet and Plasma Ratios findingsJustin Jeremiah Joseph Watson, Jamison Nielsen, Kyle Hart, et al.
Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.
Journal of Surgical Oncology|October 6, 2023
Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing mattersFranklin A Valdera, Anne E O'Shea, Todd R Smolinsky, et al.
Pageof 4